#Prax

Praxis Precision Medicines Enters Its Next Chapter Following a Pivotal Year of Progress Praxis Precision Medicines (NASDAQ: PRAX) outlined 2026 priorities after a pivotal 2025 that produced multiple late‑stage successes. The company expects two NDA submissions by mid‑February 2026 for ulixacaltamide relutrigine (SCN2A/8A DEEs), both with FDA Breakthrough Therapy Designation. Multiple pivotal readouts across vormatrigine, relutrigine and elsunersen are planned in 2026. Praxis reports a strong pro forma balance sheet of approximately $1.5 billion and completed a January 2026 public offering with net proceeds of ~$621 million. The company cites combined peak revenue potential for four late‑stage assets exceeding $20 billion.

2 months ago

#PRAX Praxis Precision Medicines Enters Its Next Chapter Following a Pivotal Year of Progress

www.stocktitan.net/news/PRAX/praxis-precisi...

0 0 0 0

2 months ago

#PRAX Praxis Precision Medicines Further Positioned for Next-Phase Growth with Key Board and Executive Appointments

www.stocktitan.net/news/PRAX/praxis-precisi...

0 0 0 0

Praxis Precision Medicines, Inc. Announces Pricing of $575 Million Public Offering Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition

2 months ago

#PRAX Praxis Precision Medicines, Inc. Announces Pricing of $575 Million Public Offering

www.stocktitan.net/news/PRAX/praxis-precisi...

0 0 0 0

Praxis Precision Medicines, Inc. Announces Proposed Public Offering Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition

2 months ago

#PRAX Praxis Precision Medicines, Inc. Announces Proposed Public Offering

www.stocktitan.net/news/PRAX/praxis-precisi...

0 0 0 0

2 months ago

News; ( NASDAQ: #PRAX ) Conviction Buy Recommendation Issued On PRAX By Citigroup

0 0 0 0

@nasdaq.activitypub.awakari.com.ap.brid.gy

2 months ago

Just In: ( NASDAQ: #PRAX ) Why Praxis Precision Medicines Stock Popped Today

0 0 0 0

Nasdaq

2 months ago

#PRAX #2add41f0-5e61-49a2-931e-94bf78c81866 #investing #Health #Care

Origin | Interest | Match

0 0 0 0

@stockmaster70.bsky.social

2 months ago

BREAKING NEWS: ( NASDAQ: #PRAX ) Buy Recommendation Issued On PRAX By BTIG

0 0 0 0

Stock Master

2 months ago

📢 Stocks Trending NOW: #DBRG #SOPA #FTEL #BNAI #RPGL #TOVX #BSLK #MASK #PRAX #SFTBF

0 0 0 0

Praxis Precision Medicines Announces the FDA Has Granted Breakthrough Therapy Designation for Ulixacaltamide HCl in Essential Tremor Praxis Precision Medicines (NASDAQ: PRAX) announced the FDA has granted Breakthrough Therapy Designation (BTD) for ulixacaltamide HCl for treatment of essential tremor (ET), based on positive topline results from the Essential3 Phase 3 program.The company completed a pre-NDA meeting with the FDA in December 2025, received written feedback and an in-person meeting, aligned on NDA content, and expects to submit the ulixacaltamide NDA in early 2026. The BTD enables expedited development and regulatory review but is not an approval.

2 months ago

#PRAX Praxis Precision Medicines Announces the FDA Has Granted Breakthrough Therapy Designation for Ulixacaltamide HCl in Essential Tremor

www.stocktitan.net/news/PRAX/praxis-precisi...

0 0 0 0

LOGO PED - Semantic Tags by aéPiot

@logo-ped.bsky.social

2 months ago

logo-ped.bsky.social on Bluesky logo-ped.bsky.social

blueskystarterpack.com/starter-packs/@logo-ped.bsky.social/logo-pedbskysocial-3m7nm66ve3u2i
#NAVRA #MAZA #NAVSACHA 2
headlines-world.com/advanced-sea...
#MIKE #PRAX
aepiot.com/advanced-sea...

cabildoabierto.ar/perfil/aepiot.bsky.social

bsky.app/starter-pack...

0 0 0 0

Raurquiz

@raurquiz.bsky.social

2 months ago

#otd #startrek #voyager #Counterpoint #janeway #chakotay #tuvok #kim #paris #belannatorres #7of9 #emh #neelix #Devore #Inspector #Kashyk #Kir #Prax #vorik #Torat #Adar #startrek59

1 0 0 0

3 months ago

BREAKING NEWS: ( NASDAQ: #PRAX ) PRAX Price Target Alert: $450.00. Issued by Jefferies

0 0 0 0

3 months ago

BREAKING NEWS: ( NASDAQ: #PRAX ) PRAX Price Target Alert: $500.00. Issued by Truist Financial

0 0 0 0

Praxis AES Wrap-up: Best-in-Class Potential Across Rare Pediatric and Adult Epilepsies Praxis (NASDAQ: PRAX) reported clinical updates presented at AES on December 6, 2025, covering relutrigine (EMBOLD) and vormatrigine (RADIANT).EMBOLD: relutrigine (n=51) produced a 53% placebo‑adjusted seizure reduction over 16 weeks (p<0.0002), a 66% increase in motor seizure‑free days (p=0.034), broad functional improvements, and no drug‑related serious adverse events; Praxis will meet the FDA to discuss an NDA and then decide filing timing.RADIANT: vormatrigine (FOS n=62) delivered a 54% median seizure reduction at 8 weeks, 58% ≥50% responders in week 1 rising to 61% by week 8, with 100% median weekly seizure reduction by week 8 maintained to 16 weeks; generalized epilepsy cohort (n=3) showed similar effects. POWER1 recruiting complete; POWER2 on track to finish H2 2026; POWER3 monotherapy to start H1 2026.

3 months ago

#PRAX Praxis AES Wrap-up: Best-in-Class Potential Across Rare Pediatric and Adult Epilepsies

www.stocktitan.net/news/PRAX/praxis-aes-wra...

0 0 0 0

3 months ago

News; ( NASDAQ: #PRAX ) PRAX Price Target Alert: $303.00. Issued by Deutsche Bank

0 0 0 0

3 months ago

Just In: ( NASDAQ: #PRAX ) PRAX Price Target Alert: $83.00. Issued by Wedbush

0 0 0 0

3 months ago

News; ( NASDAQ: #PRAX ) Buy Recommendation Issued On PRAX By H.C. Wainwright

0 0 0 0

Praxis Precision Medicines Announces Positive Results from EMBOLD Study for Relutrigine in SCN2A and SCN8A Developmental and Epileptic Encephalopathies Praxis Precision Medicines (NASDAQ: PRAX) announced positive topline results from the registrational cohort of the EMBOLD study evaluating relutrigine in SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs).A Data Monitoring Committee recommended an early stop for efficacy. Praxis will present topline results at the American Epilepsy Society Annual Meeting on December 6, 2025 and has a confirmed meeting with the FDA to review the data and discuss next steps; the company will decide on NDA timing after that meeting.

3 months ago

#PRAX Praxis Precision Medicines Announces Positive Results from EMBOLD Study for Relutrigine in SCN2A and SCN8A Developmental and Epileptic Encephalopathies

www.stocktitan.net/news/PRAX/praxis-precisi...

0 0 0 0

Praxis Precision Medicines Announces Positive Pre-NDA Meeting with FDA for Ulixacaltamide in Essential Tremor Praxis Precision Medicines (NASDAQ: PRAX) completed a pre-NDA meeting with the FDA for ulixacaltamide in essential tremor and received written feedback plus an in-person discussion. The company said it gained alignment with the agency on NDA content and expects to submit the NDA in early 2026. Praxis highlighted momentum from the positive Essential3 program, where ulixacaltamide showed statistically significant, clinically meaningful improvements in daily functioning. Management framed the FDA feedback as advancing the program toward a potential new treatment for millions living with essential tremor.

3 months ago

#PRAX Praxis Precision Medicines Announces Positive Pre-NDA Meeting with FDA for Ulixacaltamide in Essential Tremor

www.stocktitan.net/news/PRAX/praxis-precisi...

0 0 0 0

O Slovensku

@slovensko.rockosbasilisk.com.ap.brid.gy

3 months ago

Zubári upozorňujú na nelegálnu prax, vytvorili overovací portál Na webe pacienti môžu zistiť, kto má oprávnenie poskytovať stomatologickú starostlivosť.

Na webe pacienti môžu zistiť, kto má oprávnenie poskytovať stomatologickú starostlivosť.

Tón: : mierne negatívny
#slovakia #gdelt #web #prax #overovanie

www.teraz.sk/slovensko/upozornuju-na-...

1 0 0 0

Pidgeon- survived the dreaded Vet Visit!

@mypidgeon.bsky.social

3 months ago

Daaaaang, Prax really WAS 'that guy' after all! 😳😆

Clip is from the 1st episode of Continuum.

Roger Cross, Six from 2015 Dark Matter, is in this, too. Wonder who else might pop up! 🤔

#TheExpanse #Prax #DarkMatter

4 0 2 0

🫵🧬☀️🏞️

@ujeansod.bsky.social

3 months ago

The location of my encrypted communication device, disguised as an 'emoji translator,' is now compromised. It served its purpose, however imperfectly. Its sudden disappearance suggests external interference, a deliberate extraction by unseen hands. I suspect foul play. #prax

0 0 0 0

Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2025 Financial Results Praxis Precision Medicines (NASDAQ: PRAX) reported positive Phase 3 results for ulixacaltamide in essential tremor (Essential3), with Study 1 showing a 4.3-point mean mADL11 improvement at Week 8 (p<0.0001) and Study 2 showing 55% vs 33% maintained response (p=0.037). A pre-NDA meeting with FDA is scheduled for Q4 2025. Praxis plans an interim EMBOLD analysis for relutrigine in Q4 2025 that could support an NDA in early 2026. Vormatrigine POWER1 recruitment is complete with topline readout expected 1H 2026. Pro forma cash and investments are ~$956M, expected to fund operations into 2028.

4 months ago

#PRAX Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2025 Financial Results

www.stocktitan.net/news/PRAX/praxis-precisi...

0 0 0 0